36145658|t|The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells.
36145658|a|Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC (hTNBCSC) and ovarian CSC (hOvCSC) is unknown. Methods and Results: Immunophenotyping of hTNBCSC and hOvCSC was performed by flow cytometry and confirmed the expression of SORT1, and of CSC markers CD133, NANOG, and SOX2. Western blotting demonstrated the expression of the drug efflux pumps from the P-gp family members, ABCB1 and ABCB5. The cellular uptake of the fluorescent Alexa488-peptide from TH1902 was inhibited upon siRNA-mediated repression of SORT1 or upon competition with SORT1 ligands. In contrast to docetaxel, TH1902 inhibited in vitro migration, induced cell apoptosis and lead to G2/M cell cycle arrest of the hTNBCSC. These events were unaffected by the presence of the P-gp inhibitors cyclosporine A or PSC-833. In vivo, using immunosuppressed nude mice xenografts, TH1902 significantly inhibited the growth of hTNBCSC and hOvCSC xenografts (~80% vs. ~35% for docetaxel) when administered weekly as intravenous bolus for three cycles at 15 mg/kg, a dose equivalent to the maximal tolerated dose of docetaxel. Therapeutic efficacy was further observed when carboplatin was combined to TH1902. Conclusions: Overall, TH1902 exerts a superior anticancer activity than the unconjugated docetaxel, in part, by circumventing the CSC drug resistance phenotype that could potentially reduce cancer recurrence attributable to CSC.
36145658	4	10	TH1902	Chemical	-
36145658	11	28	Docetaxel Peptide	Chemical	-
36145658	74	79	Human	Species	9606
36145658	80	85	SORT1	Gene	6272
36145658	95	102	Ovarian	Disease	MESH:D010049
36145658	123	136	Breast Cancer	Disease	MESH:D001943
36145658	166	191	Breast and ovarian cancer	Disease	MESH:D061325
36145658	273	279	tumors	Disease	MESH:D009369
36145658	281	287	TH1902	Chemical	-
36145658	307	315	sortilin	Gene	6272
36145658	317	322	SORT1	Gene	6272
36145658	341	350	docetaxel	Chemical	MESH:D000077143
36145658	457	462	human	Species	9606
36145658	463	489	triple-negative breast CSC	Disease	MESH:D064726
36145658	491	498	hTNBCSC	Disease	MESH:D064726
36145658	504	511	ovarian	Disease	MESH:D010049
36145658	579	586	hTNBCSC	Disease	MESH:D064726
36145658	662	667	SORT1	Gene	6272
36145658	688	693	CD133	Gene	8842
36145658	695	700	NANOG	Gene	79923
36145658	706	710	SOX2	Gene	6657
36145658	791	795	P-gp	Gene	283871
36145658	812	817	ABCB1	Gene	5243
36145658	822	827	ABCB5	Gene	340273
36145658	868	884	Alexa488-peptide	Chemical	-
36145658	890	896	TH1902	Chemical	-
36145658	945	950	SORT1	Gene	6272
36145658	976	981	SORT1	Gene	6272
36145658	1006	1015	docetaxel	Chemical	MESH:D000077143
36145658	1017	1023	TH1902	Chemical	-
36145658	1119	1126	hTNBCSC	Disease	MESH:D064726
36145658	1180	1184	P-gp	Gene	283871
36145658	1196	1210	cyclosporine A	Chemical	MESH:D016572
36145658	1214	1221	PSC-833	Chemical	MESH:C070272
36145658	1260	1264	mice	Species	10090
36145658	1277	1283	TH1902	Chemical	-
36145658	1322	1329	hTNBCSC	Disease	MESH:D064726
36145658	1371	1380	docetaxel	Chemical	MESH:D000077143
36145658	1509	1518	docetaxel	Chemical	MESH:D000077143
36145658	1567	1578	carboplatin	Chemical	MESH:D016190
36145658	1595	1601	TH1902	Chemical	-
36145658	1625	1631	TH1902	Chemical	-
36145658	1692	1701	docetaxel	Chemical	MESH:D000077143
36145658	1793	1799	cancer	Disease	MESH:D009369
36145658	Association	MESH:D010049	6272
36145658	Negative_Correlation	MESH:C070272	283871
36145658	Association	MESH:D064726	6272
36145658	Negative_Correlation	MESH:D016572	283871
36145658	Association	MESH:D000077143	6272
36145658	Association	MESH:D001943	6272
36145658	Negative_Correlation	MESH:D000077143	MESH:D009369

